Nach Cyber-Angriff: #Ransomware-Befall bei Pharmaunternehmen #Eisai | Security https://www.heise.de/news/Ransomware-Angriff-Pharmaunternehmen-Eisai-nimmt-Systeme-offline-9182166.html #Malware #CyberCrime
#cybercrime #malware #eisai #ransomware
Alzheimer's Association campaigns for broader Leqembi coverage — FDA reverses course; will hold adcomm for Sarepta’s DMD gene therapy— Pfizer and Astellas report positive data from prostate cancer therapy trial -- See more on our front page news http://bit.ly/w28kSd #alzheimers #eisai #biogen #fda #dmd #duchenne #pfizer #astellas #clinicaltrials #prostatecancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#alzheimers #eisai #biogen #FdA #dmd #Duchenne #pfizer #astellas #clinicaltrials #ProstateCancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#FDA will review #Eisai and #Biogen’s #Alzheimers treatment #Leqembi with decision on full approval expected in early July - https://www.cnbc.com/2023/03/06/alzheimers-fda-will-review-eisais-and-biogens-treatment-leqembi-with-decision-expected-in-july.html
#fda #eisai #biogen #alzheimers #leqembi
FDA sets July decision date for full approval of Leqembi — FDA widens Lilly's Verzenio breast cancer reach — Praxis shares fall 48% following mixed data for essential tremor candidate-- See more on our front page news http://bit.ly/w28kSd #fda #alzheimers #eisai #biogen #elililly #breastcancer #essentialtremor #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#FdA #alzheimers #eisai #biogen #elililly #breastcancer #essentialtremor #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Sandoz files biosimilar of Amgen osteoporosis drug in US — Led by Merck, Vertex and Lilly, pharma's share prices largely climbed in '22 despite economic angst —Eisai gives first glimpse into Alzheimer’s drug launch -- See more on our front page news http://bit.ly/w28kSd #sandoz #biosimilars #novartis #amgen #osteoporosis #pharmastocks #merck #eisai #elililly #alzheimers #druglaunch #pharma #pharmanews #biopharma #biotech #cafepharma
#sandoz #biosimilars #novartis #amgen #osteoporosis #pharmastocks #merck #eisai #elililly #alzheimers #druglaunch #pharma #pharmanews #biopharma #biotech #cafepharma
Eisai lays off 91 staffers on its Fycompa team — Inside pharma’s push to amend new drug-pricing law —J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries -- See more on our front page news http://bit.ly/w28kSd #layoffs #eisai #drugpricing #inflationreductionact #jnj #restructuring #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#layoffs #eisai #drugpricing #InflationReductionAct #jnj #restructuring #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting — Eisai learns from Biogen’s Aduhelm disaster —5 FDA decisions to watch in the first quarter -- See more on our front page news http://bit.ly/w28kSd #mergersandacquisitions #ipsen #astrazeneca #chiesi #jpm2023 #jpm23 #biogen #eisai #aduhelm #alzheimers #fda #pharma #pharmanews #biopharma #biotech #biotechnology #cafepharma
#mergersandacquisitions #ipsen #astrazeneca #chiesi #jpm2023 #jpm23 #biogen #eisai #aduhelm #alzheimers #FdA #pharma #pharmanews #biopharma #biotech #biotechnology #cafepharma
FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)
The Foo... - https://arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda
#fda #eisai #biogen #science #approval #antibody #treatment #alzheimers #cognitivedecline
Ars Technica: FDA approves new Alzheimer’s treatment despite risks, unclear benefits https://arstechnica.com/?p=1908494 #Tech #arstechnica #IT #Technology #Cognitivedecline #Alzheimer's #treatment #antibody #approval #Science #Biogen #eisai #fda
#Tech #arstechnica #it #technology #cognitivedecline #alzheimer #Treatment #antibody #approval #science #biogen #eisai #fda
AstraZeneca deepens cancer cell therapy portfolio with Neogene buyout — Roche withdraws Tecentric for bladder cancer indication —Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal -- See more on our front page news http://bit.ly/w28kSd #astrazeneca #mergersandacquisitions #cancer #celltherapy #bladdercancer #roche #eisai #biogen #alzheimers #alzheimersdisease #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#astrazeneca #mergersandacquisitions #cancer #CellTherapy #bladdercancer #roche #eisai #biogen #alzheimers #alzheimersdisease #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#EISAI TO PRESENT FULL FINDINGS FROM #LECANEMAB CONFIRMATORY PHASE 3 - https://goo.gl/alerts/jzPNKQ #AlzheimerDisease
#eisai #lecanemab #alzheimerdisease